Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccinating Children After Chemotherapy for ALL
NCT02447718Phase 4Completed
- Sponsor
- Canadian Immunization Research Network
- Start
- Nov 2015
- Primary completion
- Mar 2018
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
A Phase 4 trial of Prevnar 13, 23-valent pneumococcal polysaccharide vaccine, diphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine in pneumococcal infection, diphtheria, Tetanus, pertussis, poliomyelitis, sponsored by Canadian Immunization Research Network. Started Nov 2015; status: completed.
02
Drugs
Prevnar 1323-valent pneumococcal polysaccharide vaccinediphtheria toxoid + tetanus toxoid + acellular pertussis vaccine + inactivated poliovirus vaccine + haemophilus influenzae type b conjugate vaccine
03
Conditions
pneumococcal infectiondiphtheriaTetanuspertussispoliomyelitis
Beyond the preview
Go deeper on NCT02447718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02447718.